Provectus Pharmaceuticals Inc. Receives US Patent Allowance to Provide Further Protection for Novel Photodynamic Drug PH-12

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has received allowance of a second US patent application protecting a novel photoactive analog of its lead photodynamic product PH-10, from the United States Patent and Trademark Office (USPTO). The pending patent covers systemic use of the drug, PH-12, for photodynamic treatment of cancer, skin diseases, and other tissue disorders using visible light activation.

Back to news